During Lymphoma Leukemia & Myeloma 2021 Virtual Congress, the Lymphoma Hub was pleased to speak to Jia Ruan, Weill Cornell Medicine, New York, US. We asked, What does the future of T-cell lymphoma management look like?
Ruan describes a promising future for T-cell lymphoma with increasingly personalized treatment, driven by precision medicine and a growing list of targeting agents. She outlines the current treatment approach, explains the impact of biological agents such as brentuximab, and describes how other novel targeted agents affect the management landscape. Finally, Ruan highlights that future studies should focus on optimizing novel agent combinations, such as romidepsin + Lenalidomide or romidepsin + Azacitidine.